TP-06 for Persistent Corneal Epithelial Defects: see if healing improves

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Capellion is a Phase 2, multicenter, randomized, double-masked trial comparing TP-06 2.0% to vehicle in up to 32 adults with persistent corneal epithelial defects that have not fully healed after at least 10 days of standard care. Participants receive the assigned treatment four times daily for 8 weeks, plus required background therapies, followed by a 2-week post-treatment observation. The study will measure complete corneal healing, healing timing and extent, visual acuity, and changes in corneal thickness to assess efficacy and safety. The trial design supports a pilot evaluation of TP-06 in this condition with close safety monitoring.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Able and willing to provide written informed consent
* Presence of a non-infected persistent corneal epithelial defect (PCED) in one eye that has failed to heal after at least 10 days of appropriate standard-of-care treatment
* Stable lesion size between Screening and Baseline as assessed by the Investigator

Exclusion Criteria:

* Active ocular infection in either eye
* Corneal perforation or high risk of corneal perforation
* Severe eyelid abnormalities
* Ocular or eyelid surgery in the study eye within 3 months prior to Baseline (unless PCED was caused by surgery)
* Use of prohibited ophthalmic medications or procedures as defined in the protocol
* Any condition that, in the Investigator's judgment, would interfere with study participation or interpretation of results

Note: Additional exclusion criteria apply, as defined in the protocol

Where it's running

• Tarsus Investigative Site
  Atlanta, Georgia, United States Recruiting
• Tarsus Investigative Site
  Alexandria, Minnesota, United States Recruiting
• Tarsus Investigative Site
  Houston, Texas, United States Recruiting
• Tarsus Investigative Site
  Sugar Land, Texas, United States Recruiting
• Tarsus Investigative Site
  Santo Domingo, Dominican Republic Recruiting
• Tarsus Investigative Site
  San Salvador, El Salvador Recruiting

Study contacts

• Study coordinator: Study Director
• Email: clinical@tarsusrx.com
• Phone: 888-421-4002

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Topical insulin drops vs amniotic membrane graft for persistent corneal epithelial defects

  We will test whether topical insulin eye drops or an amniotic membrane graft better helps heal persistent corneal epithelial defects that have not improved with standard treatment.

  Recruiting Phase 4 Al-Shifa Trust Eye Hospital · Rawalpindi, Punjab Province · NCT07561398

• Efficacy and safety of cenegermin eye drops for persistent corneal epithelial defects

  This study tests whether cenegermin eye drops can heal persistent corneal epithelial defects better than a vehicle in adults with PCED.

  Recruiting at 51 sites Phase 3 Dompé Farmaceutici S.p.A · Huntington Beach, California and 76 other locations · NCT07519902

• Topical mesenchymal stem cell secretions for persistent corneal epithelial defects

  This trial will test whether eye drops made from bone-marrow mesenchymal stem cell secretions can help adults whose corneal epithelial defects have not healed with standard treatments.

  Recruiting Phase 2 University of Illinois Chicago · Chicago, Illinois · NCT06919081

• Evaluating NEXAGON® for treating persistent corneal epithelial defects

  This study is testing if NEXAGON® eye gel can help people with stubborn corneal problems that haven't improved with regular treatments.

  Recruiting at 28 sites Phase 2 Glaukos Corporation · Dothan, Alabama and 27 other locations · NCT05966493

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.